7 Review of guidance
7.1 New treatments for chronic hepatitis C are awaiting marketing authorisation. According to clinical experts the approach to treating hepatitis C is likely to change rapidly next year because of the new technologies becoming available. The guidance on this technology will be considered for review within 1 year of publication, when other published guidance for hepatitis C is also reviewed. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.